Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Novartis has joined the swathe of big pharma companies bolstering their molecular glue degrader portfolios.

Novartis has joined the swathe of big pharma companies bolstering their molecular glue degrader portfolios.
Trump has asked pharma companies to justify efficacy for their Covid-19 drugs as he attempts to quell unrest in his administration.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Oxford University and Ellison Institute link for AI vaccine research
FDA approves mRNA vaccines for new Covid-19 season amid political tension
AI psychosis sees users ‘co-creating delusions with technology’ – expert
Opadry complete film coating system: 45 years of trust, innovation and performance